Sugi Predict

Sugi Predict / Compounds / SCHEMBL1813331

SCHEMBL1813331

SCHEMBL1813331

OS1(O)CCN(c2cc[c]cc2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.38
▸ ALDH1A1 P00352 4/20 0.34
▸ MAPT P10636 3/20 0.31
▸ KMT2A Q03164 3/20 0.31
▸ ADRA2C P18825 2/20 0.31
▸ F2 P00734 1/20 0.31
▸ PRSS1 P07477 1/20 0.31
▸ PRSS2 P07478 1/20 0.31
▸ PRSS3 P35030 1/20 0.31
▸ TMPRSS6 Q8IU80 1/20 0.31
▸ ST14 Q9Y5Y6 1/20 0.31
▸ L3MBTL3 Q96JM7 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ GFER P55789 1/20 0.31
▸ PTK2B Q14289 1/20 0.31
▸ ESR2 Q92731 1/20 0.31
▸ FAAH O00519 1/20 0.31
▸ MEN1 O00255 2/20 0.31
▸ ADRA2A P08913 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5795262 0.79 — —
SCHEMBL1032563 0.79 KDM4E (0.55) KDM4EALDH1A1KMT2AFAAHMEN1
SCHEMBL5886091 0.77 KDM4E (0.50) KDM4EALDH1A1MAPTKMT2AGAA
SCHEMBL175497 0.75 MAPT (0.59) KDM4EALDH1A1MAPTKMT2AADRA2C
SCHEMBL114702 0.75 CHKA (0.46) KDM4EALDH1A1MAPTKMT2AF2
SCHEMBL41297 0.75 CHKA (0.52) KDM4EALDH1A1MAPTKMT2AL3MBTL3
SCHEMBL27853947 0.74 F2 (0.38) KDM4EALDH1A1MAPTKMT2AADRA2C
SCHEMBL161122 0.74 ADRA2C (0.57) KDM4EALDH1A1MAPTKMT2AADRA2C
SCHEMBL1900341 0.73 ALDH1A1 (0.52) KDM4EALDH1A1MAPTKMT2AL3MBTL3
SCHEMBL146936 0.73 ALDH1A1 (0.52) KDM4EALDH1A1MAPTKMT2AL3MBTL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4352059-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2024-04-17 — — EP claimed
US-11939331-B2 Tricyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2024-03-26 — — US claimed
US-20230002385-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-01-05 — — US claimed
WO-2022261160-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2022-12-15 — — WO claimed
US-9730914-B2 3,5-diaminopyrazole kinase inhibitors Axikin Pharmaceuticals (US) 2017-08-15 — — US claimed
US-20170087131-A1 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS AXIKIN PHARMACEUTICALS, INC. 2017-03-30 — — US claimed
US-9546163-B2 3,5-diaminopyrazole kinase inhibitors AXIKIN PHARMACEUTICALS, INC. (US) 2017-01-17 — — US claimed
US-20160176857-A1 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS AXIKIN PHARMACEUTICALS, INC. 2016-06-23 — — US claimed
EP-4352059-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2024-04-17 — — EP disclosed
US-11939331-B2 Tricyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2024-03-26 — — US disclosed
US-20230002385-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-01-05 — — US disclosed
WO-2022261160-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2022-12-15 — — WO disclosed
EP-3237407-B1 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS SMA THERAPEUTICS INC (US) 2020-04-15 — — EP disclosed
EP-3237407-A1 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS Axikin Pharmaceuticals, Inc. (US) 2017-11-01 — — EP disclosed
US-7279498-B2 Substituted aryl amides as IP antagonists ROCHE PALO ALTO LLC (US) 2007-10-09 — — US disclosed
US-6998414-B2 Substituted arylamides as IP antagonists ROCHE PALO ALTO LLC (US) 2006-02-14 — — US disclosed
EP-1622611-A1 IMIDAZOLIN-2-YLAMINOPHENYL AMIDES AS IP ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-02-08 — — EP disclosed
US-20060004075-A1 Substituted aryl amides as IP antagonists ROCHE PALO ALTO LLC 2006-01-05 — — US disclosed
WO-2004096213-A1 IMIDAZOLIN-2-YLAMINOPHENYL AMIDES AS IP ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-11 — — WO disclosed
US-20040220247-A1 Substituted arylamides as IP antagonists ROCHE PALO ALTO LLC 2004-11-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004075-A1 Substituted aryl amides as IP antagonists INSR, INSRR, GIPR KDM4E 3464/4885ALDH1A1 2894/4885MAPT 4803/4885
US-20170087131-A1 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS MAP3K13, MAP3K3, PRKAG3 KDM4E 2102/4885ALDH1A1 2717/4885MAPT 2030/4885
US-20040220247-A1 Substituted arylamides as IP antagonists INSR, PTGER1, INSRR KDM4E 3971/4885ALDH1A1 2221/4885MAPT 4830/4885
US-20160176857-A1 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS MAP3K13, MAP3K3, PRKAG3 KDM4E 2102/4885ALDH1A1 2717/4885MAPT 2030/4885
US-11939331-B2 Tricyclic heterocycles as FGFR inhibitors FGFR3, FGFR1, FGFR2 KDM4E 911/4885ALDH1A1 879/4885MAPT 4197/4885
US-20230002385-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR3, FGFR1, FGFR2 KDM4E 911/4885ALDH1A1 879/4885MAPT 4197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.